Introduction
Stroke is the third leading cause of death and the leading cause of permanent disability in western countries [1] .
Due to hypoxemia in the hypoperfused brain, numerous neurons are irreversibly injured within minutes. However, in adjacent regions, which form so-called ischemic penumbra, the blood supply remains sufficient to keep neuronal cells alive for a longer period [2] . Thrombolytic treatment is aimed to save the penumbra, by possible recanalization of the occluded artery within 3-5 h of symptom onset. Irrespective of the tenfold increase of risk for intracerebral hemorrhage, intravenous thrombolysis with recombinant tissue plasminogen activator (rt-PA) greatly increases the rate of favorable outcome in acute stroke patients [3] . However, this kind of treatment is still applied to a relatively small group of patients even worldwide, due to at least three factors: a quite narrow time window for treatment, very strict inclusion/exclusion criteria and fear of adverse effects [4] [5] [6] [7] [8] [9] .
In 2003, the Croatian Ministry of Health approved rt-PA for acute treatment of ischemic stroke. For the next almost 5 years, only three centers in Croatia started this mode of treatment, among which our stroke unit covers the largest population group.
The aim of this article was to present the experience of implementing intravenous thrombolytic therapy for acute ischemic stroke in the stroke unit of University Hospital Zagreb. In our study, we analyzed the rates of patients receiving systemic thrombolytic therapy, safety and early clinical outcome in thrombolysed acute stroke patients admitted to our stroke unit in a 2-years period (May 2006 -May 2008 . The patient's clinical data (blood pressures at admission and just before administration of rt-PA), NIHSS and MRS scores (at admission, 2 h and 7th day after administering rt-PA), ''time to door'' and ''door to needle'' intervals, duration of hospital stay, as well as outcomes and complications during that time) are presented.
Methods
We retrospectively analyzed the data of 66 patients who were admitted to the stroke unit in the Department of Neurology of University Hospital Zagreb, diagnosed as an acute ischemic stroke. Patients eligible for systemic thrombolytic treatment were selected according to inclusion and exclusion criteria of the strict protocol proposed by the European Stroke Initiative [6] Selected data from each patient who received rt-PA treatment included: patient's age, gender, ''time to door'' (time interval from onset of symptoms to admission to our emergency room), ''door to needle'' (time interval from admission to our emergency room till administration of rt-PA), risk factors, blood pressure at the time of admission and just before administration of rt-PA, patient's score on the National Institute of Health Stroke Scale (NIHSS) and Modified Rankin Scale (MRS) at the time of admission, 2 h as well as 7th day after rt-PA treatment. We also compared the findings of computed tomography (CT) and/or magnetic resonance imaging (MRI) of the brain at the time of admission and 2-24 h after the administration of rt-PA therapy. In case of later clinical deterioration, neuroimaging methods were optionally performed by that time. Data considering duration of hospital treatment and eventual complications during or after rt-PA treatment (death, intracerebral hemorrhage, malignant edema) were analyzed as well. Symptomatic intracerebral hemorrhage was defined as new sign of intracerebral hemorrhage in followup CT with clinical deterioration of at least one point in the patient's NIHSS score. The dose of rt-PA was 0.9 mg per kg body weight with a maximum of 90 mg. According to protocol, 1/10 of total dose of rt-PA was given intravenously in a bolus and the remaining 9/10 during 1 h. Student's linked t tests were performed for comparison of NIHSS and MRS scores at admission and on the 7th day after rt-PA treatment administration. Non-linked student's t tests were performed for comparison of single parameters between different years.
Results
During the period of 2 years (2006-2008.) a total of 66 patients received intravenous thrombolysis (approximately 2% of all hospital admissions with diagnosis of acute stroke). All patients had symptoms of acute hemispheric stroke, and therapy was started within 3 h of symptom onset. The mean age was 65 years (range 23-80) with a male predominance (67%). The mean ''time to door'' (interval between symptom onset and arrival at the emergency room) period was approximately 62 min (range 10-120), while the mean ''door to needle'' period was approximately 71 min (range 20-120). The mean blood pressure at admission was 152/89 (range of systolic blood pressure was 105-240, while the range of diastolic blood pressure was 65-160). Mean blood pressure measured immediately prior to administering rt-PA was 149/87 (the range of systolic blood pressure was 108-210, while the range of diastolic blood pressure was 60-122). Initial median NIHSS score was 10 (range 5-22), median NIHSS 2 h post-thrombolysis was 5 (range 0-24) and seventh day after rt-PA treatment 3 (range 0-21). Initial mean MRS score was 3.99 (range 1-5), mean MRS 2 h post-thrombolysis was 2.56 (range 0-5) and 7 days post-thrombolysis was 2.52 (range 0-6). Thirteen cases of intracerebral hemorrhages or secondary hemorrhagic transformations occurred, among which seven were symptomatic. The mean duration of hospital treatment was approximately 12 days (range 5-22 days).
In 2006/2007, 21 of 1,328 acute stroke patients admitted to the stroke unit received rt-PA (1.43%), while the number in the next 1-year period increased to 45 of the total 1,445 (3.11%).
Patients treated with rt-PA showed a significant reduction in NIHSS score during the acute phase (difference in NIHSS at admission and 7 days later). Comparison of the NIHSS scores between 2-year periods did not reveal any significant difference (Table 1) . Additionally, the duration of hospital admission was constant over the years and did not show any significant change (Table 1) . During the time of hospitalization, 12 patients died (18%), from the 2nd to 10th day after thrombolysis. Two patients died due to symptomatic ICH and two deteriorated in their NIHSS score during the first 7 days after thrombolysis. Lower rate of intracerebral bleeding was observed in the 1st year (26.7%), while the percentage of lethal outcome in the same year was 19.04% (all patients died from 2 to 8 days). In the 2nd year, the percentage of lethal outcome did not significantly change (17.8%); however, six out of eight lethal outcomes had intracerebral hemorrhage and two patients died due to malignant infarction (Table 1) .
Cost-to-benefit ratio showed no difference between the two periods (Table 1) . It should be emphasized that all thrombolysed patients were admitted to the neurological intensive care unit, which anyhow has a neurologist on duty and so there is no extra cost for them.
All the results of data comparison are presented in Table 1 .
Discussion
Croatia has around 4.4 million inhabitants and about 22,000 of patients with acute stroke per year. According to our hospital registry, the incidence of ischemic stroke is approximately 1.5-2.5 stroke per 1,000 citizens and has shown slow, permanent growth over the past few years. This is in contrast to western European countries where stroke incidence decreases over the years, due mostly to better primary prevention [7] . Majority of stroke patients in Croatia are still admitted to the neurological wards, while the stroke units exist only in four university hospitals. Systemic thrombolysis with rt-PA as treatment for acute ischemic stroke received formal approval from the Croatian Ministry of Health in September 2003. Since then, thrombolytic treatment has been gradually introduced, but for the first 5 years used only in three Croatian Hospitals (two in Zagreb and one in Rijeka). During the last 12 months, thrombolytic treatment has slowly begun to reach other parts of the country and recently it is available in all university hospitals and most of the regional ones. 2007, the rate was 1.4%, while in the next 1-year period increased to 3.11%. As our hospital started with the first thrombolytic therapy in December 2005, in those first few months, only two patients (not included in this report) received rt-PA treatment. This fact was due to the not yet well-organized emergency ambulance service, (most of the patients did not reach the stroke unit within the appropriate time window) as well as slowness of emergency workup once the patient reached the hospital. An additional reason was the reluctance of the medical staff, especially neurologists, to perform thrombolysis due to fear of side effects.
However, from our data it is evident that during the observed period, intravenous thrombolysis was administered to an increasing number of patients. This can be explained in one way by the increased number of admitted stroke patients, but this would not explain the total increase of patients who received intravenous thrombolysis. The second reason is the comprehensive education and reorganization of ambulance service to treat acute stroke as a medical emergency. Additionally, as a result of a relatively aggressive campaign, the general population became more sensitive to this problem and sought medical help more promptly than in previous years. Hence, decreased problems in obtaining informed consent were also noted. From the previously mentioned facts, it is evident that more and more patients reached the neurological emergency room in the time window for thrombolytic treatment, which led to an increased rate of thrombolysed patients. On comparing the results between 2006 and 2008, it is evident that age and initial NIHSS scores of the patients receiving rt-PA remained similar through these years. There was no significant difference between ''time to door'' and ''door to needle'' time comparing the 1st and 2nd year of treatment. The drop in the range of NIHSS was significant (more than 7 points). The most significant drop did not occur soon (or in 24 h) after treating, but after several (7 days) days after treatment, suggesting that the final conclusion about the efficacy of thrombolytic treatment cannot be reached at least before the end of the 7th day after treatment.
Interestingly, during the 1st year, the rate of hemorrhagic complications or lethal outcome was quite low (1 intracerebral hemorrhage and 4 lethal outcomes among 21 treated patients); however, in 2007 these rates increased disproportionately. This could be explained, by the lower selectivity of patients, including also patients with more severe clinical presentations. The rate of hemorrhagic complications (intracerebral bleeding) and lethal outcome in 2007/2008 were 26.6 and 17.7%, respectively, and were much higher in our cohort then in previously published papers [8] . The fact that patients with more severe neurological presentation seek medical attention earlier and it is known that the outcome of such patients is worse can partly explain the higher rate of complications during the 2nd year. Another important factor is that we prolonged the therapeutic window from up to 3-5 h, following the NEJM paper [9] . Patients with complication of intracerebral hemorrhage had more severe deficits on admission (median NIHSS score 19; range [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] than the rest of the study population (median NIHSS score 10; range 5-22). However, in the National Institute of Neurological Disorders and Stroke trial [3] , the occurrence of symptomatic intracerebral hemorrhage was much lower (6.4%), but estimated only for the first 36 h after the rt-PA therapy, while in our case the observation period lasted longer. In total, during the 2 years analyzed, 7 of 12 lethal outcomes were caused by intracerebral hemorrhage, while the others died probably due to malignant hemispheric edema (5th-10th day after thrombolysis). A high rate of lethal outcomes due to malignant infarction can be explained by clinically more severe stroke (higher NIHSS score). On the other hand, late onset of intracerebral hemorrhage cannot be connected with thrombolytic treatment and should not be considered as a complication of treatment, but of the illness itself.
Compared to the SITS-MOST trial, our cohort was of similar age, with the significant prevalence of male patients [10] . We had a somewhat lower NIHSS score at admission (11 compared to 13 in SITS-MOST trial) and systolic blood pressure was 153 mmHg compared to 156 in the SITS-MOST trial and diastolic blood pressure was 90 compared to 84 mmHg in the SITS-MOST trial. Compared to this trial, we had a significantly higher rate of symptomatic intracerebral hemorrhages and lethal outcomes. Some of the reasons are discussed above, but one of the reasons for the high rate of intracerebral hemorrhage might be a systolic blood pressure above recommended limits immediately before starting rTPA. In most of the cases, blood pressure could not be lowered due to time limitations.
Over the 2 years, the rate of thrombolysed patients in our center has increased; in fact, it has doubled itself. However, these rates are still below the rate of other wellorganized stroke centers, which can be more than 20% of the admitted stroke patients. Still, a positive trend is visible, that is an increasing number of medicated patients during the following year (3.11 vs 1.43 vs 2% SIST MOST average) and the reduction in average NIHSS (from 10 to 5). The main problem remains the high rate of symptomatic intracerebral hemorrhage. It should be mentioned that our study was retrospective in nature and there was no control group, so comparing this high rate with double blind, randomized controlled trials was difficult. The conditions in the trial were strictly controlled, which is not always possible in everyday practice.
The future aim of stroke management in Croatia is the organization of a continuous and spreading network of stroke units, which will cover all parts of Croatia and allow each patient to reach the nearest stroke unit within a maximum of 60 min from onset of symptoms and, therefore, to be eligible for thrombolytic treatment. In other words, the primary goal is to increase the rate of thrombolysed patients based on better accessibility to stroke units and education of the medical staff working in ambulance services as well as neurologists. Hence, we are at the point of establishing a central stroke center in our hospital, which will offer a comprehensive management approach and also provide education for other medical employees included in acute stroke management throughout Croatia.
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